Department of Health Management Center & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Department of Hematology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Bone Marrow Transplant. 2024 Jun;59(6):785-794. doi: 10.1038/s41409-024-02243-0. Epub 2024 Feb 29.
The prevalence of osteoporosis in post stem cell transplantation (SCT) is poorly defined. We performed a systematic review and meta-analysis to determine the prevalence of osteoporosis in patients with hematologic diseases who underwent SCT. PubMed, EMBASE, and Web of Science were searched (from inception to 30th April 2023) using Medical Subject Headlines to find studies that assessed the prevalence of osteoporosis among post SCT. Thirteen articles meeting the inclusion criteria were included in the analysis. The pooled prevalence rates of osteoporosis, osteopenia, and decreased bone mineral density (BMD) were determined to be 14.2% (95% CI 9.7-18.8), 36.0% (95% CI 23.8-48.2), and 47.8% (95% CI 36.6-58.9), respectively. Substantial heterogeneity was observed among the included studies (I² values ranged from 81% to 99%). Subgroup analyses revealed variations in prevalence based on gender, follow-up duration, age, region, sample size, and study quality. These findings suggest a high prevalence of osteoporosis in post-SCT patients. Given the negative impact of osteoporosis on prognosis and recipient survival, clinicians should prioritize preventive measures, early diagnosis, and effective treatments to minimize its impact.
标题:造血系统疾病患者干细胞移植后骨质疏松症的患病率:系统评价和荟萃分析
摘要:背景:干细胞移植(SCT)后骨质疏松症的患病率定义不明确。我们进行了一项系统评价和荟萃分析,以确定接受 SCT 的血液系统疾病患者中骨质疏松症的患病率。
方法:使用医学主题词在 PubMed、EMBASE 和 Web of Science 上进行检索(从创建到 2023 年 4 月 30 日),以找到评估 SCT 后骨质疏松症患病率的研究。纳入分析的标准为评估 SCT 后骨质疏松症患病率的研究。
结果:13 篇符合纳入标准的文章被纳入分析。骨质疏松症、骨量减少和骨密度降低的汇总患病率分别为 14.2%(95%CI 9.7-18.8)、36.0%(95%CI 23.8-48.2)和 47.8%(95%CI 36.6-58.9)。纳入研究之间存在显著异质性(I²值范围为 81%-99%)。亚组分析显示,性别、随访时间、年龄、地区、样本量和研究质量等因素对患病率存在差异。
结论:这些发现表明,SCT 后患者骨质疏松症的患病率较高。鉴于骨质疏松症对预后和受者生存的负面影响,临床医生应优先采取预防措施、早期诊断和有效治疗,以最小化其影响。